FDA Issues Draft Guidance on Off-Label Statements: A New Frontier or Acknowledgement of the Status Quo?

The US Food and Drug Administration (FDA) issued a much-awaited draft guidance on October 24, revising its approach to the dissemination of scientific information on unapproved uses of approved/cleared (collectively referred to as “approved”) medical products. This draft guidance follows a series of challenges to the FDA’s prior promotional restrictions on off-label communications and citizen petitions from company coalitions.

On the whole, while the draft guidance does not represent an about-face on the FDA’s approach to communications regarding unapproved uses for approved products, it does expand the scope of such communications that the FDA is willing to permit and clarifies issues that the industry has grappled with for many years regarding circumstances under which scientific information regarding such uses can be provided to the healthcare community.

Specifically, the draft guidance outlines communications that, if undertaken in accordance with the guidance, would avoid enforcement action by the agency, including, most notably, certain content created by a firm about its own product.

SUMMARY OF THE DRAFT GUIDANCE

The draft guidance addresses circumstances under which firms can disseminate published scientific or medical journal articles (reprints) and firm-generated presentations regarding the same, as well as published clinical reference resources (clinical practice guidelines, reference texts, and independent clinical practice resources) that concern scientific information on unapproved uses (SIUU) of approved/cleared medical products.

In doing so, the FDA states that it “has sought to strike a careful balance between supporting [healthcare provider (HCP)] interest in scientific information about unapproved uses of approved/cleared medical products to inform clinical practice decisions for the care of an individual patient, and mitigating the potential that the government interests” in the statutory premarket approval requirements would be undermined.

In light of these efforts at goal balancing, the FDA has proposed an approach in developing and disseminating SIUU communications that would avoid enforcement by the FDA (by not being considered evidence of a new intended use of a product), summarized as follows:

• Any communications regarding SIUU would need to be truthful, non-misleading, factual, and unbiased, and would need to provide HCPs all information that may be necessary to understand the “strengths and weaknesses and validity and utility” of the information being conveyed. This would require firms to include certain disclosures as part of SIUU communications, many of which are similar to the FDA’s prior guidance on Distributing Scientific and Medical Publications on Unapproved New Uses (Reprint Guidance), as well as the FDA’s guidance on Medical Product Communications That Are Consistent With the FDA-Required Labeling.
• SIUU communications would only be based on certain source publications, specifically medical journal articles or published clinical reference resources that meet certain FDA-enumerated publication standards.
• The source publication that serves as the basis for the SIUU communication would need to be scientifically sound and would need to provide information that is relevant to HCPs making clinical practice decisions regarding the care of an individual patient (i.e., the information would need to be clinically relevant). To meet this standard, the source publication would need to, at a minimum, meet generally accepted design and methodological standards for the particular type of study or analysis, taking into account established scientific principles and current scientific knowledge. This would include randomized, double-blind, concurrently controlled superiority studies, as well as other “well-designed and well-conducted trials.” Real-world data and evidence may also meet this standard, depending on the characteristics of the data and the nature of the specific analyses. Conversely, studies without adequate comparison or control groups, individual case reports, and reports that do not contain sufficient detail to permit a scientific evaluation of the underlying information would not meet this standard. Early-stage studies are also “unlikely to be sufficiently reliable by themselves to allow for a determination of clinical relevance.” Whether any particular study or source publication meets this standard would be an individualized analysis based on any scientific or data limitations.
• Unlike the Reprint Guidance, which prohibited firms from summarizing or characterizing a source publication, the SIUU guidance permits firms to present SIUU information that is based upon a qualifying source publication provided that the following factors are met:
  • The presentation would need to clearly and prominently include the required disclosures and would not be permitted to use “persuasive marketing techniques,” including, but not limited to, celebrity endorsements, premium offers, and gifts. The FDA would look for any indication that the firm is attempting to influence HCPs to reach a positive conclusion about the unapproved use, other than via the unbiased scientific content of the communication.
  • SIUU information presentations would need to be separate and distinct from promotional communications, a concept that may not be new to many in the industry. This would mean separating promotional content and SIUU information into different communications, as well as using “vehicles, channels, and venues” for sharing SIUU communications that are different and distinct from those used for promotional communications, such as the current practice of maintaining a clear division between a firm’s marketing/promotional content and personnel and medical affairs activities. For smaller firms where such a division may not be possible, the FDA states that the company “should ensure that SIUU communications are clearly identified and distinct from promotional communications about approved uses.” To accomplish these ends, the FDA also recommends that websites contain separate pages for promotional communications and SIUU communications and that these pages not cross-link to each other.
  • Firms should only use platforms to communicate SIUU information that allows for full compliance with the guidance, including the inclusion of all necessary disclosures. This means that certain social media platforms with space limitations may not be appropriate. The FDA does state, however, that a firm could use a social media platform to announce a new publication and link to a website with an SIUU communication that is compliant with the guidance.
  • To ensure that HCPs fully understand an SIUU communication, the FDA recommends that firms use plain and clear language for any company-developed portions of a communication, including the FDA-recommended disclosure.
  • Firm-generated presentations should be accompanied by the full underlying reprint. However, per the FDA, “firms should not rely upon the accompanying reprint(s) to provide information that is material to the representations made in the firm-generated presentation; all information material to the representations… should be included with those representations within the firm-generated presentation….”
  • Firm presentations should not imply that the information “represents larger or more general experience with the medical product than it actually does;” decontextualize the presented information such that HCPs do not have the information necessary to interpret the strengths, weaknesses, validity, and utility of the data; represent or suggest product safety or efficacy in a way that is “not consistent with the reprint;” make conclusions or representations regarding an unapproved use, “even if an accurate reflection of the statements in the reprint, without attributing that statement expressly to the reprint” and without contiguous disclosures regarding author-firm affiliations; employ statistics to imply the clinical significance or validity of data when not supported; or otherwise use tables, graphs, or presentational elements to distort or misrepresent the data.

  KEY TAKEAWAYS

  As specifically noted by the FDA, dissemination of SIUU information in accordance with the new guidance would not be the only way that companies may engage in communications regarding unapproved uses of approved products. Companies may still avail themselves of the FDA’s guidance on Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices, Industry-Supported Scientific and Educational Activities, and Drug and Device Manufacturer Communications with Payors, Formulary Committees, and Similar Entities (and associated statutory provisions).

  The FDA further states, “it has long been FDA policy not to consider a firm’s presentation of truthful and non-misleading scientific information about unapproved uses at the planned sessions and presentations at medical or scientific conferences to be evidence of intended use when the presentation is made in non-promotional settings and not accompanied by promotional communications.” Accordingly, the SIUU guidance would provide companies with an additional avenue to communicate scientific information to the medical community.

  Notably, in some ways, the draft SIUU guidance would expand the scope of information on which firms would be able to rely when disseminating information regarding unapproved uses of approved products. Unlike the FDA’s prior guidance on the dissemination of reprints that required that studies be well-controlled clinical investigations, the SIUU guidance provides for other kinds of studies so long as they are scientifically sound and clinically relevant. This, however, would require firms to assess whether the new FDA standard is met for source publications and firm-generated material. It also would require firms to periodically reassess source publications to confirm that they continue to meet FDA standards (e.g., to confirm that there have not been any new findings that may undermine a publication’s clinical relevance). This would require that companies establish processes to scientifically and clinically assess source publications, both initially and following initial approval of a publication’s use.

  In other ways, however, the SIUU guidance may be intended to restrict the scientific information that may be disseminated by companies. Under the FDA’s regulations and the agency’s long-standing policy, the agency does “not intend to restrict the full exchange of scientific information concerning [a] drug, including dissemination of scientific findings in scientific or lay media.” This did not rule out the presentation of internally generated data that may not yet be published.

  Further, under the SIUU guidance, companies with approved products that intend to disseminate SIUU information may only rely on published scientific or medical journal articles and clinical reference resources to fit within the FDA’s communicated enforcement policy. This would not, notably, include unpublished data on file.

  Finally, while not explicitly stated, the SIUU guidance would clarify the question regarding whether information on unapproved uses that are disseminated in the form of reprints and clinical practice resources, and other presentations based on the same, may be proactively distributed by a company or whether they may only be distributed in response to an unsolicited request for information, an area that has historically raised questions within the industry.

  Based on the guidance’s discussions regarding posting SIUU information to company websites and dissemination via social media, the FDA appears to settle this question by indirectly stating that SIUU information that complies with the guidance may be proactively communicated.

  CONCLUSION

  On the whole, the new draft SIUU guidance would provide some necessary clarity in the space, providing companies with greater certainty on the scope of scientific information that may be disseminated, as well as how such information may be communicated to the medical community.

  Impacted stakeholders may wish to submit comments to the FDA regarding the policies proposed in the draft guidance (comments are due by December 26, 2023) and begin to consider how the FDA’s draft guidance recommendations may be successfully implemented.

  Contacts

  If you have any questions or would like more information on the issues discussed in this LawFlash, please contact any of the following: